Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany.
Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S43-6. Epub 2013 Oct 3.
Treatment of patients suffering from active ankylosing spondylitis (AS) with TNFα blockers, has been shown to result in clinically significant improvement of signs and symptoms of the disease. Long-term extension studies with these agents have shown sustained clinical efficacy for up to 10 years in patients who continued treatment. However, only a few studies have examined whether reduction of dosage of discontinuation of anti-TNF therapy is possible. In daily clinical practice, prolongation of treatment intervals is frequently tried in patients who are in clinical remission for longer periods of time, but no data on the success of that are available. Discontinuation of treatment is usually needed in patients who want to become pregnant, and in patients with severe infections. This review summarises what is known on the topic of discontinuation of biologic treatment in patients with AS.
治疗患有活动性强直性脊柱炎（AS）的患者，使用 TNFα 阻滞剂已被证明可显著改善疾病的体征和症状。这些药物的长期扩展研究表明，在继续治疗的患者中，长达 10 年的时间内持续具有临床疗效。但是，只有少数研究检查了减少剂量或停止抗 TNF 治疗是否可行。在日常临床实践中，对于长时间处于临床缓解期的患者，经常尝试延长治疗间隔，但尚无关于该方法成功的数据。在希望怀孕的患者和患有严重感染的患者中，通常需要停止治疗。这篇综述总结了关于 AS 患者停止生物治疗的已知信息。
